Optimizing Nav1.7‐Targeted Analgesics: Revealing Off‐Target Effects of Spider Venom‐Derived Peptide Toxins and Engineering Strategies for Improvement

The inhibition of Nav1.7 is a promising strategy for the development of analgesic treatments. Spider venom‐derived peptide toxins are recognized as significant sources of Nav1.7 inhibitors. However, their development has been impeded by limited selectivity. In this study, eight peptide toxins from t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advanced science 2024-11, Vol.11 (42), p.e2406656-n/a
Hauptverfasser: Luo, Sen, Zhou, Xi, Wu, Meijing, Wang, Gongxin, Wang, Li, Feng, Xujun, Wu, Hang, Luo, Ren, Lu, Minjuan, Ju, Junxian, Wang, Wenxing, Yuan, Lei, Luo, Xiaoqing, Peng, Dezheng, Yang, Li, Zhang, Qingfeng, Chen, Minzhi, Liang, Songping, Dong, Xiuming, Hao, Guoliang, Zhang, Yunxiao, Liu, Zhonghua
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The inhibition of Nav1.7 is a promising strategy for the development of analgesic treatments. Spider venom‐derived peptide toxins are recognized as significant sources of Nav1.7 inhibitors. However, their development has been impeded by limited selectivity. In this study, eight peptide toxins from three distinct spider venom Nav channel families demonstrated robust inhibition of hNav1.7, rKv4.2, and rKv4.3 (rKv4.2/4.3) currents, exhibiting a similar mode of action. The analysis of structure and function relationship revealed a significant overlap in the pharmacophore responsible for inhibiting hNav1.7 and rKv4.2 by HNTX‐III, although Lys25 seems to play a more pivotal role in the inhibition of rKv4.2/4.3. Pharmacophore‐guided rational design is employed for the development of an mGpTx1 analogue, mGpTx1‐SA, which retains its inhibition of hNav1.7 while significantly reducing its inhibition of rKv4.2/4.3 and eliminating cardiotoxicity. Moreover, mGpTx1‐SA demonstrates potent analgesic effects in both inflammatory and neuropathic pain models, accompanied by an improved in vivo safety profile. The results suggest that off‐target inhibition of rKv4.2/4.3 by specific spider peptide toxins targeting hNav1.7 may arise from a conserved binding motif. This insight promises to facilitate the design of hNav1.7‐specific analgesics, aimed at minimizing rKv4.2/4.3 inhibition and associated toxicity, thereby enhancing their suitability for therapeutic applications. This study reveals that the off‐target Kv4.2/4.3 may be a common action mechanism of Nav1.7 peptide inhibitors from spider venoms. Pharmacophore‐guided rational design is used to engineer an optimized mGpTx1‐SA, which improves Nav1.7 selectivity, reduces side effects, and enhances analgesic efficacy. This underscores the value of considering off‐target effects and provides a strategy for rational Nav1.7 analgesic design with minimal side effects.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202406656